AREVA Med:  Developing Nuclear Medicine for Tomorrow’s Cancer Treatments

AREVA Med is a nuclear biotech company developing innovative therapies in oncology. AREVA Med has developed new processes for producing lead-212 (212Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative and promising approach of nuclear medicine allowing to recognize and destroy cancer cells while limiting the impact on nearby healthy cells. With its partners, AREVA Med pursues the development of effective therapies to address cancer patients’ needs. AREVA Med is the medical subsidiary of the AREVA group.

Orano Med Video

Click here to view the latest Orano Med Video


For more information about Orano Med, please contact:
Alison Tise
Tel.: + 1 (301) 841-1673